248282-18-0

Usage

Uses

Used in Pharmaceutical Industry:
3-Quinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-5-Methoxy-1-Methyl-2-oxois used as an antimalarial agent for its strong inhibition of the enzyme dihydroorotate dehydrogenase, which is necessary for the growth of the malaria parasite. This makes it a promising candidate for the development of new treatments against malaria.
Used in Antiviral Applications:
In the field of antiviral research, 3-Quinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-5-Methoxy-1-Methyl-2-oxohas shown potential as an antiviral agent. Its ability to target and inhibit specific viral processes makes it a candidate for further studies and development to combat viral infections.
Used in Anticancer Applications:
3-Quinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-5-Methoxy-1-Methyl-2-oxois also being explored for its potential as an anticancer agent. Its mechanism of action and ability to target cancer cells have generated interest in its use for developing novel cancer therapies.
Used in Research and Development:
Due to its therapeutic potential, 3-Quinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-5-Methoxy-1-Methyl-2-oxois extensively used in research and development for the treatment of various diseases. Ongoing studies aim to understand its full potential and optimize its use in medical applications.

Upstream product

• 248282-13-5 1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxylic acid ethyl ester 
• 53600-33-2 6-methoxyanthranilic acid 
• 67765-42-8 5-methoxy-2,4-dihydro-1H-3,1-benzoxazine-2,4-dione 
• 91105-97-4 5-methoxy-1-methyl-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 
• 254964-68-6 6-methoxy-N-methyl-anthranilic acid 
• 1332581-19-7 2-methoxy-6-(methylamino)benzonitrile 
• 1897-52-5 2,6 difluorobenzonitrile 

Downstream Products

• 254964-60-8 1,2-dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide 

Relevant academic research and scientific papers

Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure-Activity Relationship

Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).

QUINOLINE DERIVATIVES

The invention is related to compounds of general formula (I), wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R' is methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, or OCHxFy, wherein x = O - 2, y = 1 - 3 with the proviso that x + y = 3; R'' is hydrogen, fluoro or chloro; with the proviso that R'' is fluoro or chloro only when R' is fluoro; R4 is hydrogen or pharmaceutically acceptable inorganic or organic cations; R5 is ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, trifluoromethyl, OCHxFy, or OCH2CHxFy wherein x = 0 - 2, y = 1 - 3 with the proviso that x + y = 3; R6 is hydrogen; or R5, and R6 taken together are methylenedioxy; and any tautomer thereof. The invention also relates to pharmaceutical compositions containing a compound of general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering of a compound having formula (I) to said mammal.

Quinoline derivatives

The invention relates to compounds of general formula (I) wherein R is selected from ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec.-butyl and allyl; R4 is selected from hydrogen and pharmaceutically acceptable inorganic and organic cations; R5 is selected from methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, CF3, and OCHxFy; wherein x=0-2, y=1-3 with the proviso that x+y=3; R6 is hydrogen; or R5 and R6 taken together are methylenedioxy; and any tautomer hereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods of treating mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering a compound having the formula (I) to said mammal.

Quinoline derivatives

The invention is related to compounds of general formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R' is methyl, methoxy, fluoro, chloro, bromo, trifluoromethyl, or OCHxFy, wherein x=0-2, y=1-3 with the proviso that x+y=3, R'' is hydrogen, fluoro or chloro; with the proviso that R'' is fluoro or chloro only when R' is fluoro or chloro; R4 is hydrogen or pharmaceutically acceptable inorganic or organic cations; R5 is ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, trifluoromethyl, OCHxFy, or OCH2CHxFy wherein x=0-2, y=1-3 with the proviso that x+y=3; R6 is hydrogen; or R5 and R6 taken together are methylenedioxy; and any tautomer thereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of the compounds of formula (I), as well as methods for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation by administering of a compound having the formula (I) to said mammal.